JNJ - הכנסה לפני ניכוי ריבית, מסים ופחת J&J

High R&D expenditures and patent protection create a formidable barrier to entry for competitors. The operating profit (EBIT) trend, where the metric value stands at 33682.94, confirms Johnson & Johnson (JNJ) as the gold standard of reliability in medicine. Inelastic demand and the ability to index product pricing guarantee the holding company stable returns regardless of inflationary pressures.

A defensive portfolio requires rigorous screening of assets' operational efficiency. This indicator measures cash flow from core operations before deducting financial and non-cash expenses, determining the business's baseline profitability. For Johnson & Johnson (JNJ), this metric reflects the high margins generated by scaling patented medical technologies. Analyzing absolute EBITDA allows for the identification of trend reversal points. The price action of this absolute EBITDA prevents overpaying for the asset.